Our highlights from this year’s American College of Cardiology Scientific Sessions in Chicago, USA (29-31 March 2025), extend across encouraging results on ANGPTL3 inhibition with solbinsiran in mixed dyslipidaemia and SHR-1918 in sub-optimally controlled hyperlipidaemia, mechanistic and resource utilisation data supporting olezarsen in familial chylomicronaemia syndrome, latest insights from the PROMINENT trial of pemafibrate, and changing trends in prescribing of TG-lowering medicines.
Read the reports:
- PROLONG-ANG3: durable TG reductions with solbinsiran
- Encouraging Phase 2 data with SHR-1918 in patients at CV risk
- Mechanistic and resource utilisation data support olezarsen in FCS
- PROMINENT analysis investigates apoB and LDL-C impact on CV outcomes
- Changing trends in use of TG-lowering therapies
Reporting by Jenny Bryan
